I am the MND Association Lady Edith Wolfson and ALS Association’s Milton Safenowitz Senior Fellow. I trained in medicine in Egypt and earned my MSc and PhD in Clinical Neuroscience from King’s College London. My research group uses big data for precision medicine, optimizing clinical trials, and enhancing drug discovery.

Research Focus:

• Complex disease genetics and precision medicine
• Big data application and AI in clinical trials and drug discovery
• Development of proteomic-based biomarkers for Neurodegeneration
• Structural variation analysis in genomics

I chair the Trans-Ancestral Genetics working group in Project MinE and lead the Drug Discovery and Trials Optimisation Working Group in the DEMON network, applying AI to dementia research. I co-founded the Alan Turing Institute Interest Group in Precision Dementia Medicine and the Alzheimer’s Association group on AI for Precision Dementia Medicine. I am an EDI Theme Representative at the NIHR Maudsley BRC.

Please see my Research Staff Profile for more detail

Key publications

• Fang et al., 2018. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol.
• Al Khleifat et al., 2021. Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis. NPJ Genom. Med.
• Krannich et al., 2023. VariantSurvival: A tool to identify genotype-treatment response. Front. bioinform.
• Iacoangeli et al., 2019. DNAscan : Personal computer compatible NGS analysis, annotation and visualisation. BMC Bioinform.
• Ashton et al., 2021. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat. Commun.

View all publications

Key collaborators

• The Project MinE Consortium
• Professor Ammar Al-Chalabi, King's College London
• Professor David Llewellyn, University of Exeter Medical School and the Alan Turing Institute
• Professor Henrik Zetterberg, University of Gothenburg